Cargando…

Correction to: Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies

Detalles Bibliográficos
Autores principales:	Williams, David M., Evans, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846638/ https://www.ncbi.nlm.nih.gov/pubmed/33417153 http://dx.doi.org/10.1007/s13300-020-00976-x

Ejemplares similares

Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
por: Williams, David M., et al.
Publicado: (2020)

Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues—Liraglutide and Semaglutide
por: Basalay, Maryna V., et al.
Publicado: (2019)

Advances in GLP-1 treatment: focus on oral semaglutide
por: Eliaschewitz, Freddy G., et al.
Publicado: (2021)

The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
por: Chuong, Vicky, et al.
Publicado: (2023)

Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)
por: Femminella, Grazia Daniela, et al.
Publicado: (2020)

Correction to “Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes”
Publicado: (2022)

Correction to: Immunotherapy in prostate cancer: new horizon of hurdles and hopes
por: Tsaur, Igor, et al.
Publicado: (2021)

Counselling Patients for GLP-1 Analogue Therapy: Comparing GLP-1 Analogue with Insulin Counselling
por: Kalra, Sanjay, et al.
Publicado: (2012)

Correction to: New horizons in holistic, person-centred health promotion for hearing healthcare
Publicado: (2023)

Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study
por: Richards, Jesse, et al.
Publicado: (2023)

DNAism: exploring genomic datasets on the web with Horizon Charts
por: Rio Deiros, David, et al.
Publicado: (2016)

Correction: Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands
Publicado: (2020)

Correction to: Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects
por: van Hout, Marloes, et al.
Publicado: (2023)

Absence of QTc Prolongation with Sodium N-(8-[2-Hydroxybenzoyl] Amino) Caprylate (SNAC), an Absorption Enhancer Co-Formulated with the GLP-1 Analogue Semaglutide for Oral Administration
por: Granhall, Charlotte, et al.
Publicado: (2021)

Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
por: Sposito, Andrei C., et al.
Publicado: (2019)

Correction to: Racial and Ethnic Disparities in Financial Barriers Among Overweight and Obese Adults Eligible for Semaglutide in the United States
Publicado: (2023)

Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide
por: McLean, Brent A., et al.
Publicado: (2021)

GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway
por: Xiang, Jie, et al.
Publicado: (2023)

Correction to: Review of global neurosurgery education: Horizon of Neurosurgery in the Developing Countries
por: Kato, Y., et al.
Publicado: (2020)

Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study
por: Lingvay, Ildiko, et al.
Publicado: (2021)

The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study
por: Ozeki, Yoshinori, et al.
Publicado: (2022)

Correction to: Disease progression, treatments, hospitalization, and clinical outcomes in acute GVHD: a multicenter chart review
por: Holtan, Shernan G., et al.
Publicado: (2022)

The effects of GLP-1 analogues on pre-diabetes of the children
por: Zhou, Qing-Xia, et al.
Publicado: (2017)

Correction: A Decline in Benthic Foraminifera following the Deepwater Horizon Event in the Northeastern Gulf of Mexico
por: Schwing, Patrick T., et al.
Publicado: (2015)

Publisher Correction: Brain charts for the human lifespan
por: Bethlehem, R. A. I., et al.
Publicado: (2022)

Navigating the Minefield of Computational Toxicology and Informatics: Looking Back and Charting a New Horizon
por: Patlewicz, Grace
Publicado: (2020)

Analogue gravity phenomenology: analogue spacetimes and horizons, from theory to experiment
por: Faccio, Daniele, et al.
Publicado: (2013)

Correction: Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with Type 2 Diabetes in Treatment Intensification: A Retrospective Observational Single-Center Study
por: Yamada, Hodaka, et al.
Publicado: (2023)

Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
por: Stafford, Sara, et al.
Publicado: (2022)

Correction: Advanced Neuromonitoring Modalities on the Horizon: Detection and Management of Acute Brain Injury in Children
por: Ko, Tiffany S., et al.
Publicado: (2023)

Correction: The Development and Characteristics of Ancient Harbours—Applying the PADM Chart to the Case Studies of Ostia and Portus
por: Salomon, Ferreol, et al.
Publicado: (2017)

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
por: Meier, Juris J., et al.
Publicado: (2021)

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea
por: Kårhus, Martin Lund, et al.
Publicado: (2022)

Correction to: Managing pollution from antibiotics manufacturing: charting actors, incentives and disincentives
por: Nijsingh, Niels, et al.
Publicado: (2019)

Correction: Making space to learn about teaching: expanding teaching horizons through postgraduate education
por: Aitken, Gillian, et al.
Publicado: (2022)

The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis
por: Alhindi, Yousef, et al.
Publicado: (2022)

Measuring the universe: our historic quest to chart the horizons of space and time
por: Ferguson, Kitty
Publicado: (1999)

Correction to “Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes” (J Clin Endo Metab Case Reports. 2023; 1(1): 10.1210/jcemcr/luac017)
Publicado: (2023)

Correction to: Cerebrolysin for the Treatment of Aneurysmal Subarachnoid Hemorrhage in Adults: A Retrospective Chart Review
por: Park, Yung Ki, et al.
Publicado: (2019)

Polymorphisms of GLP-1 Receptor Gene and Response to GLP-1 Analogue in Patients with Poorly Controlled Type 2 Diabetes
por: Lin, Chia-Hung, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lif1der7pqvkhulfoc9f4as4k8